Search Results - "Fauble, Veena D."

Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis by Jain, Tania, Kunze, Katie L., Mountjoy, Luke, Partain, Daniel K., Kosiorek, Heidi, Khera, Nandita, Hogan, William J., Roy, Vivek, Slack, James L., Noel, Pierre, Fauble, Veena D. S., Leis, Jose F., Sproat, Lisa, Tefferi, Ayalew, Patnaik, Mrinal M., Mesa, Ruben A., Palmer, Jeanne

“…Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in myelofibrosis in the early post-HCT period have not been defined thus far…”
Get full text

109-P by Endres, Robert O, Hoffman, Arthur D, Scott, Ian, Souza, Stephanie, Marlowe, Melissa, Medis, Robin, Fauble, Veena D, Slack, James L

“…Aim Hematopoietic stem cell transplant patients are tested for HLA antibodies if potential donors are unrelated donors with mismatched HLA antigens. If…”
Get full text

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis by Palmer, Jeanne, Kosiorek, Heidi E., Wolschke, Christine, Fauble, Veena D.S., Butterfield, Richard, Geyer, Holly, Scherber, Robyn M., Dueck, Amylou C., Gathany, Allison, Mesa, Ruben A., Kroger, Nicolaus

“…•Patients report that at 1 year following bone marrow transplant, they have a better quality of life than before transplant.•Measurement of patient-reported…”
Get full text

Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation in Adults Using Fludarabine, Carmustine, Melphalan, and Antithymocyte Globulin: Outcomes Depend on Disease Risk Index but Not Age, Comorbidity Score, Donor Type, or Human Leukocyte Antigen Mismatch by Slack, James L, Dueck, Amylou C, Fauble, Veena D, Sproat, Lisa O, Reeder, Craig B, Noel, Pierre, Khera, Nandita, Betcher, Jeffery A, Klein, Jared L, Leis, Jose F, Adams, Roberta H

“…Abstract Although reduced-intensity conditioning has become standard of care for patients with hematologic malignancies undergoing allogeneic hematopoietic…”
Get full text

Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis by Palmer, Jeanne, Kosiorek, Heidi E., Wolschke, Christine, Fauble, Veena D.S., Butterfield, Richard, Geyer, Holly, Scherber, Robyn M., Dueck, Amylou C., Gathany, Allison, Mesa, Ruben A., Kroeger, Nicolaus

“…Background: Myelofibrosis (MF) is a bone marrow disorder characterized by anemia, splenomegaly and constitutional symptoms. There has been substantial work…”
Get full text

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial by Gathany, Allison, Scherber, Robyn M., Girardo, Marlene, Kosiorek, Heidi E., Dueck, Amylou C., Geyer, Holly, Fauble, Veena D.S., Vannucchi, Alessandro M., Fuentes, Ana Kerguelen, Andersen, Christen Lykkegaard, Ejerblad, Elisabeth, Birgegard, Gunnar, Johansson, Peter L., Andreasson, Bjorn, Ross, David M, Sackman, Federico, Demory, Jean-Loup, Tam, Constantine S., Michiels, Jan J., Radia, Deepti, Ewing, Joanne, Wadelin, Frances, Lown, Robert N., McMullin, Mary Frances, Swe, Wunna, Cullis, Jonathan O., Sargant, Nigel, Moreton, Paul, Cargo, Catherine, Sekhar, Mallika, Shekouhi, Satareh, Mesa, Ruben A.

“…Background: Myeloproliferative neoplasms (MPN) including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) are clonal hemopathies…”
Get full text

109-P: DECLINE OF HLA ANTIBODIES IN A HEMATOPOIETIC STEM CELL TRANSPLANT PATIENT by Endres, Robert O., Hoffman, Arthur D., Scott, Ian, Souza, Stephanie, Marlowe, Melissa, Medis, Robin, Fauble, Veena D., Slack, James L.

“…Hematopoietic stem cell transplant patients are tested for HLA antibodies if potential donors are unrelated donors with mismatched HLA antigens. If…”
Get full text

Quality of Life Following Allogeneic Stem Cell Transplant for MF by Palmer, Jeanne, Kosiorek, Heidi E., Fauble, Veena DS, Geyer, Holly, Dueck, Amylou C., Mesa, Ruben A.

“…Background: Myelofibrosis (MF) is a myeloproliferative neoplasm that is characterized by significant scar tissue and fibrosis in the bone marrow, enlarged…”
Get full text

Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis by Jain, Tania, Temkit, M'hamed, Partain, Daniel K., Patnaik, Mrinal M, Slack, James L., Khera, Nandita, Hogan, William J., Roy, Vivek, Noel, Pierre, Leis, Jose F, Sproat, Lisa, Fauble, Veena DS, Mesa, Ruben A., Palmer, Jeanne

“…Background: Donor cell chimerisms are tested at frequent intervals after allogeneic hematopoietic stem cell transplantation (alloHSCT). However, the predictive…”
Get full text

PBSCT without the Use of Growth Factors Post Transplant: Cost Savings without Clinical Consequences. Is It Time for a Change in Standard Practice? by Schriber, Jeffrey, MD, Simpson, Eileen, BS, MT, Fauble, Veena, MD, Go, Aileen, MD, Szetela, Andrew, PharmD, BCOP, Kendrick, Selma, RN MS, Abbas, Jonathan, M.D, Briggs, Adrienne, MD

Get full text

Post Transplant Cytoxan in Patients over the Age of 60 Undergoing Allogeneic Transplant: Less Graft Versus Host Disease (GVHD) Related Deaths Than in Patients Treated with Standard Tacrolimus Methotrexate by Schriber, Jeffrey, MD, Fauble, Veena, MD, Simpson, Eileen, BS, MT, Steenstra, Kate, MS, FNP, Chiffelle, Rochelle, DNP, Sulski, Gail, MS, FNP, Thurman, Nicole, MS, FNP, Go, Aileen, MD, Kendrick, Selma, RN MS, Abbas, Jonathan, M.D, Briggs, Adrienne, MD

Get full text

Folinic Acid Rescue after Methotrexate Graft Versus Host Disease Prophylaxis to Reduce Mucositis and Improve the Probability of Day +11 Methotrexate Administration - Role of the Hematopoietic Cell Transplant Pharmacist in Development of Program Guidelines by Betcher, Jeffrey, BSPharm, Shelton, Travis, PharmD, Slack, James L., MD, Leis, Jose, MD, PhD, Fauble, Veena, MD, Sproat, Lisa Ostrosky, MD, MSW, Palmer, Jeanne, MD, Noel, Pierre, MD

Get full text

Ruxolitinib Prior to Allogeneic Stem Cell Transplant: The Experience at Mayo Clinic Arizona by Fauble, Veena, MD, Noel, Pierre, MD, Mesa, Ruben A., MD, FACP, Adams, Roberta, MD, Leis, Jose, MD, PhD, Khera, Nandita, MD, Sproat, Lisa Ostrosky, MD, MSW, Palmer, Jeanne, MD, Betcher, Jeffrey, BSPharm, Slack, James L., MD

Get full text

Outcomes of Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia by Olsen, Jane, NP, Wu, Qing, Khera, Nandita, MD, Adams, Roberta, MD, Fauble, Veena, MD, Leis, Jose, MD, PhD, Noel, Pierre, MD, Palmer, Jeanne, MD, Slack, James L., MD, Sproat, Lisa Ostrosky, MD, MSW

Get full text

Central Nervous System Leukemia in Acute Myeloid Leukemia by Altriki, Mohamad, MD, Cheng, Meng-Ru, Fauble, Veena, MD, Khera, Nandita, MD, Leis, Jose, MD, PhD, Mesa, Ruben A., MD, FACP, Noel, Pierre, MD, Slack, James L., MD, Tibes, Raoul, MD, PhD, Sproat, Lisa Ostrosky, MD, MSW

Get full text

Factors Affecting the Incidence of Severe (Stage 2-4) Gastrointestinal (GI) Graft-Versus-Host Disease (GVHD) in Adult Patients (pts) Undergoing Allogeneic Hematopoietic Transplant (Allo-HCT) for Hematologic Malignancy by Betcher, Jeffrey, R.Ph, Chang, Yu-Hui, MPH, Ph.D, Noel, Pierre, MD, Leis, Jose, MD, PhD, Sproat, Lisa Ostrosky, MD, MSW, Fauble, Veena, MD, Khera, Nandita, MD, Adams, Roberta, MD, Slack, James L., MD

Get full text